AUG 8·SEC EDGARLow
Dambkowski Carl sold $738K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $134.17 ($0.74M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$APGE
Apogee Therapeutics, Inc.
Price · $APGEvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $APGEMore →
AUG 5·yahoo.com
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Health Care Fund’s Q2 2026 investor letter reported the fund gained 11.99% in the quarter. It said it sold Apogee Therapeutics (NASDAQ:APGE) after Apogee agreed to be acquired by AbbVie (AbbVie Inc.) for $135.11 per share, a 49.5% premium. APGE closed at $134.19 on Aug. 4, 2026.
JUL 20·fool.com
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
AbbVie (ABBV) said June 22 it will acquire Apogee Therapeutics (APGE) for $10.9 billion in cash. The deal would add zumilokibart for eczema to AbbVie’s immunology portfolio. The article discusses potential effects on AbbVie’s dividend, citing AbbVie’s 2025 free cash flow estimate of $17.8 billion and its dividend growth record.
APGE sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning APGE (Apogee Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent APGE coverage spans mergers & acquisitions, insider activity and financial news.
In the last 30 days, APGE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($738K). The most active reporter was Dambkowski Carl, Chief Medical Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving APGE
This is a routine 10b5-1 insider sale disclosure, not a fundamental company update, but it can still affect near-term sentiment.
The article reinforces that APGE is in an announced AbbVie acquisition, with a defined offer price and a premium that can anchor trading and spread behavior.
The article provides no new Apogee-specific fundamentals beyond its role as the acquisition target.
APGE has a direct takeover headline, typically driving spread compression and deal-arb dynamics.
Insider selling is largely pre-planned and partially non-market (gift), so it is unlikely to signal near-term fundamental deterioration.
alphai scores every news story that mentions APGE with an AI model for sentiment and relevance, and aggregates insider trades from Apogee Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $APGE
Score
Dambkowski Carl sold $738K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $134.17 ($0.74M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min readBaron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Health Care Fund’s Q2 2026 investor letter reported the fund gained 11.99% in the quarter. It said it sold Apogee Therapeutics (NASDAQ:APGE) after Apogee agreed to be acquired by AbbVie (AbbVie Inc.) for $135.11 per share, a 49.5% premium. APGE closed at $134.19 on Aug. 4, 2026.
2 min read
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
AbbVie (ABBV) said June 22 it will acquire Apogee Therapeutics (APGE) for $10.9 billion in cash. The deal would add zumilokibart for eczema to AbbVie’s immunology portfolio. The article discusses potential effects on AbbVie’s dividend, citing AbbVie’s 2025 free cash flow estimate of $17.8 billion and its dividend growth record.
7 min read
Big Pharma’s $300 Billion Patent Problem Fuels Biotech Deals
PwC estimates over $300 billion in branded pharma revenue will lose patent exclusivity by decade end, driving large drugmakers to buy pipelines. ALPS Advisors says biopharma deal value could exceed $250B in 2026. The ALPS Medical Breakthroughs ETF (SBIO) added 37 names in June; it holds ABBV’s $10.9B Apogee deal target APGE and Definium (DFTX).
7 min readWhat This Apogee Insider Move Might Mean After a 247% Stock Run
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson filed an SEC Form 4 showing he disposed of 95,046 shares on July 8 and July 10, 2026. Of this, 75,046 shares were gifted to a donor-advised fund and 20,000 were sold under a Rule 10b5-1 plan. Henderson retained about 920,941 shares. APGE reported a TTM net loss of $274.6 million and its stock rose about 247% over the prior year.
7 min readHENDERSON MICHAEL THOMAS sold $2.7M of APGE
HENDERSON MICHAEL THOMAS (Chief Executive Officer) sold 20,000 shares of Apogee Therapeutics, Inc. (APGE) at $133.63 ($2.67M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
2 min readDambkowski Carl sold $730K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $132.74 ($0.73M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read
Biotech Gives SBIO Its Best Month Since 2023
In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).
4 min readAbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie and Apogee Therapeutics said June 22 they signed a definitive agreement for AbbVie to acquire Apogee. AbbVie will pay $135.11 per share in cash, valuing Apogee at about $10.9 billion. Both boards approved unanimously, and AbbVie expects closing in fiscal Q3 2026, subject to shareholder and regulatory approvals.
4 min readAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie (NYSE: ABBV) agreed to acquire Apogee Therapeutics (NASDAQ: APGE) to expand its immunology and respiratory pipeline. AbbVie will pay $135.11 per share in cash, valuing Apogee at about $10.9 billion. Apogee’s lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13 and TSLP for asthma. The deal is expected to close in Q3 2026, subject to approvals.
6 min read